Novavax COVID-19 Vaccine Becomes <br />5th to Reach Phase 3 Trial in the US.<br />On Monday, Novavax announced the beginning <br />of its Phase 3 trial for its vaccine candidate, <br />named NVX-CoV2373, in the U.S. and Mexico.<br />This trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world's population, Novavax President and CEO Stanley C. Erck, via news release.<br />The trial will evaluate safety, efficacy <br />and immune response in up to<br />30,000 people aged 18 and over.<br />The company also aims for at least <br />25% of participants to be age 65 <br />or older and at least 15% to be Black.<br />Johnson & Johnson expects results from its Phase 3 trial <br />of a single-dose vaccine by January or February
